Canada · Health Canada Drug Product Database

APO-NAPROXEN / ESOMEPRAZOLE

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 106723
DIN: 02564548
Form: Tablet (Immediate- And Delayed-Release)
Company as listed by source: APOTEX INC
Source status: Marketed (2026-07-21)
Source last updated: 2026-07-23

Source-listed ingredients

NAPROXEN — 500 MG
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) — 20 MG

These values do not establish equivalence or a dose recommendation.

Packages

Package details are not available in this snapshot.

Source and coverage

Open Health Canada Drug Product Database →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse Canada records →